Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Targeting bone metastases in prostate cancer: improving clinical outcome.

Body JJ, Casimiro S, Costa L.

Nat Rev Urol. 2015 Jun;12(6):340-56. doi: 10.1038/nrurol.2015.90. Review.

PMID:
26119830
2.

Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.

Vignani F, Bertaglia V, Buttigliero C, Tucci M, Scagliotti GV, Di Maio M.

Cancer Treat Rev. 2016 Mar;44:61-73. doi: 10.1016/j.ctrv.2016.02.002. Review.

PMID:
26907461
3.

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Ryan CJ, Saylor PJ, Everly JJ, Sartor O.

Oncologist. 2014 Oct;19(10):1012-8. doi: 10.1634/theoncologist.2013-0472. Review.

4.

Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.

Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F.

Eur Urol. 2015 Nov;68(5):850-8. doi: 10.1016/j.eururo.2015.06.039. Review.

PMID:
26153564
5.

Management of bone metastases in prostate cancer: a review.

Bienz M, Saad F.

Curr Opin Support Palliat Care. 2015 Sep;9(3):261-7. doi: 10.1097/SPC.0000000000000157. Review.

PMID:
26262831
6.

Pathologic fracture in patients with metastatic prostate cancer.

Gartrell BA, Saad F.

Curr Opin Urol. 2014 Nov;24(6):595-600. doi: 10.1097/MOU.0000000000000105. Review.

PMID:
25166424
7.

Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.

Graff JN, Beer TM.

Oncology (Williston Park). 2015 Jun;29(6):416-23. Review.

8.
9.

Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.

Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, Shore N, Oudard S, Karsh L, Carducci M, Damião R, Wang H, Ying W, Goessl C.

Eur Urol. 2015 Jul;68(1):42-50. doi: 10.1016/j.eururo.2014.10.001.

PMID:
25449207
10.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Review.

PMID:
26196735
11.

Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.

Blacksburg SR, Witten MR, Haas JA.

Curr Treat Options Oncol. 2015 Mar;16(3):325. doi: 10.1007/s11864-014-0325-1. Review.

PMID:
25777571
12.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology..

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Review.

PMID:
24321502
13.

Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer.

Dellis A, Papatsoris AG.

Expert Opin Biol Ther. 2014 Jan;14(1):7-10. doi: 10.1517/14712598.2013.840582.

PMID:
24074253
14.

Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.

Zustovich F, Fabiani F.

Crit Rev Oncol Hematol. 2014 Aug;91(2):197-209. doi: 10.1016/j.critrevonc.2014.01.003. Review.

PMID:
24503416
15.

Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.

Shirley M, McCormack PL.

Drugs. 2014 Apr;74(5):579-86. doi: 10.1007/s40265-014-0198-4. Review.

PMID:
24610703
16.

Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.

Borsò E, Boni G, Galli L, Ricci S, Farnesi A, Mazzarri S, Cianci C, Mariani G, Falcone A.

Future Oncol. 2015;11(2):323-31. doi: 10.2217/fon.14.157.

PMID:
25075962
17.
18.

New and emerging therapies for bone metastases in genitourinary cancers.

Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K.

Eur Urol. 2013 Feb;63(2):309-20. doi: 10.1016/j.eururo.2012.10.007. Review.

19.

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.

Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H, Braun A, Fizazi K.

Ann Oncol. 2015 Feb;26(2):368-74. doi: 10.1093/annonc/mdu519. Erratum in: Ann Oncol. 2015 Jun;26(6):1274.

20.

Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.

Dellis A, Papatsoris A.

Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):5-10. doi: 10.1586/14737167.2016.1123624. Review.

PMID:
26588857
Items per page

Supplemental Content

Support Center